Printer Friendly

THE IMMUNE RESPONSE CORP. CONFIRMS SCHEDULE FOR COMPLETION OF PHASE II/III CLINICAL TRIAL IN 1992

 THE IMMUNE RESPONSE CORP. CONFIRMS SCHEDULE
 FOR COMPLETION OF PHASE II/III CLINICAL TRIAL IN 1992
 SAN DIEGO, March 9 /PRNewswire/ -- The Immune Response Corp. (NASDAQ-NMS: IMNR) announced today that a phase II/III clinical trial of the company's HIV therapeutic vaccine is on schedule for completion in September 1992, as previously announced.
 The phase II/III trial is being sponsored by a joint venture between Immune Response and Rhone-Poulenc Rorer Inc. This trial is a double- blind, placebo-controlled efficacy study measuring the effect of treatment with the HIV therapeutic vaccine on 103 HIV-infected patients in the early asymptomatic stages of this infection. The primary objective of the current phase II/III clinical trial is to provide the data necessary to support a Product License Application planned for 1993 and to secure Food and Drug Administration approval for commercial marketing of the HIV therapeutic vaccine.
 "We are pleased with the progress of our clinical trials for the HIV therapeutic vaccine. The principal initial application of the HIV therapeutic vaccine, if successfully developed, will be to prevent or delay the development of AIDS in HIV-infected individuals," said James B. Glavin, president and chief executive officer of The Immune Response Corp.
 An article in the March 6, 1992 issue of The Wall Street Journal that referred to the status of a planned study in uninfected volunteers has inadvertently created confusion about the company's clinical trials. The development status of a preventive vaccine for individuals not infected with HIV is unrelated to the current trials on the HIV therapeutic vaccine, which is intended only for already-infected patients.
 The Immune Response Corp. is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS and for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
 -0- 3/9/92
 /CONTACT: Steven Basta of Immune Response, 619-431-7080/
 (IMNR) CO: The Immune Response Corp. ST: California IN: MTC SU: PDT


KJ-EH -- SD004 -- 6199 03/09/92 08:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1992
Words:337
Previous Article:IN FOCUS SYSTEMS APPOINTS NEW CHIEF EXECUTIVE OFFICER
Next Article:WESTON AND FEHILY TIMONEY FORM ENVIRONMENTAL ENGINEERING VENTURE
Topics:


Related Articles
THE IMMUNE RESPONSE CORPORATION PCR ASSAY CORRELATES VIRAL BURDEN WITH CLINICAL STAGE OF HIV INFECTION
WYETH-AYERST BEGINS TESTING LIPOSOMAL FLU VACCINE; THE LIPOSOME COMPANY'S NEW ADJUVANT MAY BOOST PROTECTION
RIBI IMMUNOCHEM SCIENCE UPDATE
LONG-TERM FOLLOW-UP DATA PUBLISHED ON INITIAL PATIENTS TREATED WITH REMUNE(TM)
ATTENTION BUSINESS EDITORS:
Biomira's Bridging Study Fully Enrolled to Test Theratope(R) Cancer Vaccine
Biomira Announces Interim Bridging Study Results for THERATOPE(R) Vaccine.
Biomira Begins Second Stage of Phase II BLP25 Cancer Vaccine Clinical Trial.
Biomira Provides BLP25 Vaccine Program Update.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters